Coronavirus Update: Novavax Launches Phase III Trial In UK As Virus Surges Back
Plus: Bharat Biotech Licenses Washington University Vaccine
Executive Summary
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
You may also be interested in...
Novavax May Seek COVID-19 Vaccine Emergency Authorization In US Based On UK Data
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.
Novavax May Seek COVID-19 Vaccine Emergency Authorization In US Based On UK Data
With its US/Mexico Phase III trial delayed due to manufacturing questions, Novavax has aligned its UK study with FDA guidance. It hopes for interim data from that study during Q1 2021.
Waters Muddied As Bharat Readies COVID-19 Vaccine For '21 Launch
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.